Tirzepatide vs Semaglutide for Weight Loss
Tirzepatide (Zepbound) and semaglutide (Wegovy) represent the leading pharmacological options for chronic weight management. Tirzepatide’s dual GIP/GLP-1 receptor agonism produces greater weight loss than semaglutide’s selective GLP-1 agonism, but the practical implications depend on dose, tolerability, cost, and clinical context.
Mechanism of Action
Section titled “Mechanism of Action”Semaglutide: GLP-1R Agonism
Section titled “Semaglutide: GLP-1R Agonism”Semaglutide is a pure GLP-1 receptor agonist. GLP-1R activation in the hypothalamus (arcuate nucleus, paraventricular nucleus) reduces appetite and food intake. Peripheral GLP-1R effects include delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression. The net effect is reduced caloric intake of approximately 20–30% from baseline.
Tirzepatide: Dual GIP/GLP-1 Agonism
Section titled “Tirzepatide: Dual GIP/GLP-1 Agonism”Tirzepatide is a dual GIP/GLP-1 receptor agonist with differential affinity: GIPR EC₅₀ ~0.14 nM vs. GLP-1R EC₅₀ ~0.18 nM. The GIPR component contributes approximately 5–10% additional weight loss beyond GLP-1R agonism alone through:
- Enhanced adipose tissue lipid mobilization
- Synergistic appetite suppression via central GIPR circuits
- Improved insulin sensitivity and glucose disposal
- Potentiation of GLP-1-mediated insulin secretion
The synergistic mechanism produces greater weight loss at equivalent or lower doses than semaglutide.
Comparison Table
Section titled “Comparison Table”| Property | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Mechanism | GIP/GLP-1 dual agonist | GLP-1R selective agonist |
| Max approved dose | 15 mg weekly | 2.4 mg weekly |
| Half-life | ~116 hrs (5 days) | ~165 hrs (7 days) |
| Max weight loss | ~20–21% body weight | ~15–17% body weight |
| ≥20% weight loss rate | ~56% of participants | ~32% of participants |
| HbA1c reduction | ~2.4–2.6% | ~1.5–1.8% |
| GI side effects | Moderate | Moderate |
| Injection frequency | Once weekly | Once weekly |
| Oral option | No | Yes (Rybelsus, not for obesity) |
Clinical Trial Evidence
Section titled “Clinical Trial Evidence”STEP Trials (Semaglutide 2.4 mg)
Section titled “STEP Trials (Semaglutide 2.4 mg)”The STEP program established semaglutide’s efficacy for obesity:
- STEP-1 (n=1961): 14.9% weight loss at 68 weeks vs. 2.4% placebo. 86.4% achieved ≥5% loss, 69% achieved ≥10% loss, 50% achieved ≥15% loss.
- STEP-2 (n=1210): 9.6% weight loss in T2D patients vs. 3.4% placebo. HbA1c reduction 1.6%.
- STEP-3 (n=611): 16.0% with intensive behavioral therapy vs. 5.7%.
- STEP-4 (n=902): 17.4% sustained loss with continued treatment vs. 5.6% regain after placebo switch.
SURMOUNT Trials (Tirzepatide)
Section titled “SURMOUNT Trials (Tirzepatide)”The SURMOUNT program established tirzepatide’s efficacy for obesity:
- SURMOUNT-1 (n=2539): 20.9% weight loss with 15 mg at 72 weeks vs. 3.1% placebo. 56% achieved ≥20% loss, 73% achieved ≥15% loss, 85% achieved ≥10% loss.
- SURMOUNT-2 (n=938): 12.8–14.7% weight loss in T2D patients vs. 3.2% placebo.
- SURMOUNT-3 (n=2435): 24.3% with intensive lifestyle intervention vs. 2.1%.
- SURMOUNT-4 (n=938): 25.4% with continued treatment vs. 14.1% regain after switch to placebo.
SURPASS-2 (Direct Comparison)
Section titled “SURPASS-2 (Direct Comparison)”SURPASS-2 compared tirzepatide to semaglutide 1 mg (diabetes dose, not obesity dose):
- Tirzepatide 15 mg: 2.46% HbA1c reduction, 11.7 kg weight loss
- Semaglutide 1 mg: 1.84% HbA1c reduction, 5.7 kg weight loss
Tirzepatide was superior at all doses. However, semaglutide was dosed at 1 mg, not the obesity dose of 2.4 mg. Extrapolation to obesity treatment requires caution.
Weight Loss Efficacy
Section titled “Weight Loss Efficacy”Dose-Response Comparison
Section titled “Dose-Response Comparison”| Dose | Tirzepatide Weight Loss | Semaglutide Weight Loss |
|---|---|---|
| Low dose | ~8% (5 mg) | ~6% (0.5 mg) |
| Mid dose | ~12% (10 mg) | ~10% (1.0 mg) |
| Max dose | ~20–21% (15 mg) | ~15–17% (2.4 mg) |
| Max approved | 15 mg weekly | 2.4 mg weekly |
Responders by Threshold
Section titled “Responders by Threshold”| Weight Loss Threshold | Tirzepatide 15 mg | Semaglutide 2.4 mg |
|---|---|---|
| ≥5% body weight | ~92% | ~86% |
| ≥10% body weight | ~85% | ~69% |
| ≥15% body weight | ~73% | ~50% |
| ≥20% body weight | ~56% | ~32% |
Tirzepatide achieves greater weight loss at every responder threshold. The 20% weight loss threshold, which approaches bariatric surgery efficacy, is achieved by over half of tirzepatide-treated patients but only one-third of semaglutide-treated patients.
HbA1c Reduction
Section titled “HbA1c Reduction”Both agents produce clinically meaningful HbA1c reductions, though tirzepatide’s dual mechanism achieves greater reductions:
| Dose | Tirzepatide HbA1c Reduction | Semaglutide HbA1c Reduction |
|---|---|---|
| Low dose | ~1.5% (5 mg) | ~1.0% (0.5 mg) |
| Mid dose | ~2.0% (10 mg) | ~1.5–1.8% (1.0 mg) |
| Max dose | ~2.4–2.6% (15 mg) | ~2.0% (2.0 mg) |
Tirzepatide achieves approximately 0.5–0.8% greater HbA1c reduction at equivalent doses, likely reflecting additive GIPR-mediated insulin sensitization and secretion.
GI Side Effects
Section titled “GI Side Effects”The GI side effect profile is broadly similar between agents, though semaglutide may produce slightly more nausea:
| Side Effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | 12–31% | 20–44% |
| Diarrhea | 12–17% | 12–30% |
| Vomiting | 5–12% | 8–24% |
| Decreased appetite | 11–18% | 15–26% |
| Constipation | 11–18% | 16–24% |
Tirzepatide’s slightly lower nausea rates may relate to GIPR-mediated attenuation of GLP-1R-driven emetic responses. Both agents use dose titration over 4–8 weeks to mitigate initial GI effects.
Dosing Escalation
Section titled “Dosing Escalation”Tirzepatide
Section titled “Tirzepatide”| Phase | Dose | Duration |
|---|---|---|
| Initiation | 2.5 mg weekly | 4 weeks |
| Escalation 1 | 5.0 mg weekly | 4+ weeks |
| Escalation 2 | 7.5 mg weekly | 4+ weeks |
| Escalation 3 | 10.0 mg weekly | 4+ weeks |
| Maximum | 15.0 mg weekly | Ongoing |
Semaglutide
Section titled “Semaglutide”| Phase | Dose | Duration |
|---|---|---|
| Initiation | 0.25 mg weekly | 4 weeks |
| Escalation 1 | 0.5 mg weekly | 4 weeks |
| Escalation 2 | 1.0 mg weekly | 4 weeks |
| Escalation 3 | 1.7 mg weekly | 4 weeks |
| Maintenance | 2.4 mg weekly | Ongoing |
Both agents use 4-week titration intervals. Tirzepatide has 5 dose levels; semaglutide has 5 dose levels. Both allow dose maintenance at any level if tolerability is limiting.
Cost and Insurance Coverage
Section titled “Cost and Insurance Coverage”| Factor | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| List price (monthly) | ~$1,023–1,059 | ~$1,349–1,500 |
| Insurance coverage | Expanding (diabetes + obesity) | Established (obesity) |
| Prior authorization | Often required | Often required |
| Manufacturer coupons | Available | Available |
| Out-of-pocket | $25–500/month with coverage | $25–500/month with coverage |
Tirzepatide has a lower list price than semaglutide for obesity. Insurance coverage for both agents is expanding as payers recognize the cost-effectiveness of pharmacological obesity treatment.
When to Choose Which
Section titled “When to Choose Which”Tirzepatide may be preferred when:
- Maximum weight loss is the primary goal
- Greater HbA1c reduction is needed (T2D + obesity)
- Patient has failed semaglutide or other GLP-1 RAs
- Cost is comparable or favors tirzepatide
- Tolerability at higher doses is acceptable
Semaglutide may be preferred when:
- Longer clinical track record is desired
- Insurance coverage favors Wegovy
- Oral option (Rybelsus) is needed (non-obesity indication)
- Simpler mechanism of action is preferred
- Patient experiences GI intolerance on tirzepatide
References
Section titled “References”- Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).” NEJM 2022;387:205-216.
- Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity (STEP 1).” NEJM 2021;384:989-1002.
- Frías JP, et al. “Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).” NEJM 2023;388:523-534.
- Garvey WT, et al. “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-2).” Lancet 2022;400:1426-1437.
- Davies MJ, et al. “Semaglutide 2.4 mg once weekly in adults with overweight or obesity (STEP 2).” Lancet 2021;397:1003-1012.